Stock OBSEF OBSEVA SA
Add to a list
To use this feature you must be a member
Log inSign up

Financials ObsEva SA OTC Markets

Equities

OBSEF

CH1260041939

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 19:27:45 26/04/2024 BST 		5-day change 1st Jan Change
0.005 USD +150.00% Intraday chart for ObsEva SA +150.00% -85.71%
04-03 ObsEva to Delist from the SIX Swiss Exchange MT
03-20 ObsEva SA Announces to Wind-Down the Operations CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022
Capitalization 1 573.8 156.8 132.4 165.1 18.07
Enterprise Value (EV) 1 435.1 114.5 128.2 137 12.67
P/E ratio -6.68 x -1.44 x -1.3 x -2.61 x -0.45 x
Yield - - - - -
Capitalization / Revenue 38,251 x - - - 0.92 x
EV / Revenue 29,009 x - - - 0.65 x
EV / EBITDA -5.65 x -1.07 x -1.61 x -2.52 x -0.81 x
EV / FCF -12.1 x -2.01 x -3.02 x -16.2 x -0.47 x
FCF Yield -8.27% -49.8% -33.2% -6.18% -211%
Price to Book 3.77 x 3.25 x 14.9 x 5 x 1.83 x
Nbr of stocks (in thousands) 44,946 43,799 61,161 81,580 125,075
Reference price 2 12.77 3.580 2.165 2.024 0.1444
Announcement Date 05/03/19 05/03/20 05/03/21 10/03/22 31/03/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.016 0.015 - - - 19.64
EBITDA 1 -67.39 -77.04 -107 -79.6 -54.28 -15.66
EBIT 1 -67.46 -77.15 -107.1 -79.7 -54.51 -15.68
Operating Margin -421,650% -514,360% - - - -79.83%
Earnings before Tax (EBT) 1 -66.88 -76.76 -108.7 -82.93 -58.16 -29.87
Net income 1 -66.93 -76.72 -108.8 -82.97 -58.38 -29.88
Net margin -418,287.5% -511,440% - - - -152.16%
EPS 2 -2.250 -1.910 -2.491 -1.670 -0.7754 -0.3245
Free Cash Flow 1 -34.73 -35.98 -56.98 -42.51 -8.464 -26.75
FCF margin -217,035.16% -239,841.67% - - - -136.23%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 09/03/18 05/03/19 05/03/20 05/03/21 10/03/22 31/03/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3
Net sales 1 0.006 0.004 20.1 0.005 2.237 2.612 3.712
EBITDA -19.52 - - - - - -
EBIT 1 -19.7 -18.37 1.532 -17.98 -10.6 -31.41 -0.629
Operating Margin -328,350% -459,225% 7.62% -359,520% -474.03% -1,202.53% -16.95%
Earnings before Tax (EBT) 1 -19.98 -19.11 0.838 -19.91 -11.75 -32.74 -12.11
Net income 1 -20 -19.14 0.819 -20.05 -11.8 -32.8 -12.06
Net margin -333,400% -478,600% 4.08% -400,960% -527.54% -1,255.67% -324.81%
EPS - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 06/05/21 05/08/21 04/11/21 10/03/22 17/05/22 17/08/22 01/12/22
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 111 139 42.3 4.24 28.1 5.4
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -34.7 -36 -57 -42.5 -8.46 -26.8
ROE (net income / shareholders' equity) -84.3% -56.9% -111% -290% -287% -279%
ROA (Net income/ Total Assets) -46.7% -31.9% -49.3% -58.8% -44.1% -24.2%
Assets 1 143.5 240.8 220.5 141.1 132.3 123.6
Book Value Per Share 2 3.370 3.380 1.100 0.1500 0.4000 0.0800
Cash Flow per Share 2 3.050 3.190 1.560 0.5400 0.6800 0.0800
Capex 1 0.19 0.19 0.05 0.01 0.01 -
Capex / Sales 1,181.25% 1,253.33% - - - -
Announcement Date 09/03/18 05/03/19 05/03/20 05/03/21 10/03/22 31/03/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. OBSN Stock
  4. OBSEF Stock
  5. Financials ObsEva SA